

Identity:

Title: MD, MHA

Director of the cardiovascular clinics and Head of the Heart Failure service

Family Name(s): Laufer-Perl

First Name(s): Michal

Age: 44

Photo:**Application for the following position in the HFA Board or Nominating Committee:**

Ordinary Board members

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	Tel Aviv Sourasky Medical Center, Israel
Department:	Cardiology
Address:	6 Weizmann st, Tel Aviv
Post code / Zip:	6423906
Country:	Israel

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

I serve as the Director of the cardiovascular clinics, and Head of the Heart Failure service at Tel Aviv Sourasky Medical Center. Additionally, I hold the position of Secretary of the Cardiomyopathy Section within the Israel Cardiology Association.

My contributions to the HF community include:

1. Promoting HF – Over the past 5 years, I have spearheaded the number of our facility's HF clinics from 2 to 11 per week, facilitating a total of 2800 visits annually, marking a remarkable 180% increase.
2. Advanced HF care – as the Head of the HF daycare unit, we provide unique repetitive intermittent IV inotropes therapies including Milrinone and Levosimendan, as detailed in a recent publication in Clin Cardiol (2022;45(5):488-94).
3. Remote GDMT up-titration – collaborating with the Israel Ministry of Health, I have contributed to the development of a smartphone application designed to supervise the up-titration of GDMT, integrating patients' vital signs, steps, blood tests, quality of life questionnaires, to optimize GDMT.
4. Academic engagement – As a senior lecturer at the Tel Aviv Faculty of Medicine and applied for clinical associate Professor, I'm actively involved in mentoring doctoral students, guiding interns, and delivering lectures at numerous HF conferences. Additionally, I organize biannual conferences on cardiomyopathies and HF as part of my role in the Israel Cardiology Association. Moreover, I have a Master of Health Administration (MHA) degree from the Guilford Glazer School of Business and Management, and I serve as an ad hoc reviewer for several journals (JACC CardioOncology, ESC HF, Canadian Journal of Cardiology), while also holding editorial positions in Cardio-Oncology journal and the European Journal of Medical Research.
5. PI role – I serve as a PI in several HF clinical trials including ALLAY-HF, CORDIO, and RELIEVE-HF trial, on which I'm an author in the main results paper soon to be published. Moreover, I served as the PI in the ESC HFIII registry.

6. Research - I have published 54 original papers, with 29 as a leading author, and presented 35 abstracts at international conferences, including the ESC, ESC HFA, ACC, and AHA. I'm actively engaged in a number of international collaborations, including the ICI-Myocarditis registry led by Prof. Javid Moslehi (JAMA Cardiol. 2021;6(11):1329-37), development of an AI model for CV risk assessment in cancer patients in partnership with the University of Illinois (Eur Heart J Digit Health. 2023 May 8;4(4):302-31), and with both the RELIEVE-HF and ALLAY-HF teams, with pending publications. Additionally, I have received research grants from several pharma companies, totaling ~230 000 USD over 2019-2022.
7. Innovative programs – I initiated the cardio-oncology clinic in 2016, now the largest in Israel, complemented by a prospective registry (ICOR) and an innovative cancer rehabilitation program in 2022, offering comprehensive support to cancer survivors through multidisciplinary interventions, and supported by the Israel Cancer Association.

Top publications:

1. Clin Res Cardiol. 2023;112(3):409-18.
2. Eur Heart J Cardiovasc Imaging. 2022;23(8):1055-65.
3. ESC Heart Fail. 2022;9(2):1487-91.
4. J Immunother. 2021;44(5):179-84.
5. JAMA Cardiol. 2021;6(11):1329-37
6. Clin Res Cardiol. 2021;110(1):50-60.
7. J Am Soc Echocardiogr. 2021;34(12):1273-1284.e9
8. J Am Soc Echocardiogr. 2021;34(6):642-52
9. Eur Heart J Cardiovasc Imaging. 2021;22(11):1241-54.
10. Clin Res Cardiol. 2020;109(2):255-62.

H index 16

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

I'm presently a fellow of the ESC and previously held the role of the Israeli representative of the Heart Failure Specialists of Tomorrow (HoT) from 2018 to 2021. Since 2021 and continuing until 2025, I serve as the Secretary of the Cardiomyopathy Section within the Israel Cardiology Association. In this capacity, I organize biannually conferences focused on cardiomyopathies and HF and oversee clinical education for cardiology interns. Additionally, I provide medical opinions for drug Registration for the Israel Ministry of Health.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

It would be a tremendous honor for me to become a part of the HFA board and contribute to shaping the trajectory of HF management. I see this role as an opportunity to promote national projects to an international level. I strongly believe in the importance of addressing HF as a major epidemic in the developed world, which remained undereducated and underdiagnosed. Therefore, there is significant work to be done in enhancing education, diagnosis, and implanting novel treatments and follow-up strategies.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

As I believe that being a part of the HFA committee holds immense potential for advancing HF education and pioneering new projects, I'm fully committed to making this my top priority.